Bosulif FDA Approval History
FDA Approved: Yes (First approved September 4, 2012)
Brand name: Bosulif
Generic name: bosutinib
Dosage form: Tablets and Capsules
Company: Pfizer Inc.
Treatment for: Chronic Myelogenous Leukemia
Bosulif (bosutinib) is a kinase inhibitor for use in the treatment of chronic myelogenous leukemia (CML).
- Bosulif is indicated for the treatment of:
- adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.
- adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Development timeline for Bosulif
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
